Toronto Dominion Bank cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 888,253 shares of the biopharmaceutical company’s stock after selling 106,659 shares during the period. Toronto Dominion Bank owned 0.07% of Gilead Sciences worth $68,344,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of GILD. Twin Focus Capital Partners LLC boosted its position in Gilead Sciences by 2.1% during the first quarter. Twin Focus Capital Partners LLC now owns 6,537 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 137 shares during the period. Malaga Cove Capital LLC increased its stake in Gilead Sciences by 0.6% in the 2nd quarter. Malaga Cove Capital LLC now owns 24,813 shares of the biopharmaceutical company’s stock worth $1,909,000 after purchasing an additional 143 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Gilead Sciences by 4.2% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 3,605 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 144 shares during the last quarter. Anderson Fisher LLC lifted its stake in Gilead Sciences by 0.9% in the second quarter. Anderson Fisher LLC now owns 17,237 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 149 shares during the period. Finally, Archford Capital Strategies LLC increased its position in Gilead Sciences by 1.5% during the 2nd quarter. Archford Capital Strategies LLC now owns 9,912 shares of the biopharmaceutical company’s stock valued at $763,000 after purchasing an additional 149 shares during the period. 77.87% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently issued reports on GILD shares. Raymond James reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Tuesday, June 30th. DZ Bank restated a “buy” rating on shares of Gilead Sciences in a research report on Monday, June 15th. TheStreet downgraded Gilead Sciences from a “b” rating to a “c” rating in a report on Thursday, July 30th. Finally, Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday, August 19th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have issued a buy rating to the company. Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $78.78.

NASDAQ:GILD traded down $0.55 during mid-day trading on Wednesday, reaching $65.65. The company’s stock had a trading volume of 557,775 shares, compared to its average volume of 15,544,973. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 1.22. The stock has a market cap of $83.00 billion, a P/E ratio of -276.16, a PEG ratio of 0.67 and a beta of 0.56. The firm’s fifty day moving average price is $67.74 and its two-hundred day moving average price is $73.87. Gilead Sciences, Inc. has a 12-month low of $60.89 and a 12-month high of $85.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.46). Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.24 billion. Analysts predict that Gilead Sciences, Inc. will post 6.95 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.68 per share. The ex-dividend date of this dividend is Monday, September 14th. This represents a $2.72 dividend on an annualized basis and a yield of 4.14%. Gilead Sciences’s dividend payout ratio is presently 44.30%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: What is a dead cat bounce?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.